Hanmi launches Nexium competitor in the US
This article was originally published in Scrip
AstraZeneca's blockbuster PPI Nexium (esomeprazole magnesium) has a new competitor in the US market in the form of an esomeprazole strontium product sold by Hanmi Pharmaceutical and its US marketing partner Amneal Pharmaceuticals.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.